Biotech Industry Examiner

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

The rovadicitinib deal is about more than one blood-cancer and

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

A new generation of biotech start-ups is trying to “rejuvenate”

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

High cholesterol has long been a silent threat lurking in

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

When Dr. Peter Marks walked out of the FDA’s headquarters

From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle

From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle

Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall

Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities

Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities

In the rapidly advancing field of precision medicine, where treatments

Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results

Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results

Obesity remains a critical public health challenge in the United

Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

BioArctic, a Swedish biotechnology company renowned for its innovative approach

Scroll to Top